Low-Dose Immunotherapy in Head and Neck Cancer: A Randomized Study
Journal of Clinical Oncology · 10.01.2023 · 41 (2) · 222-232
DOI: 10.1200/jco.22.01015 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Clinical Oncology, erschienen am 10.01.2023. Verfasst von Vijay Maruti Patil und 26 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Tata Memorial Hospital, Homi Bhabha National Institute (HBNI), Mumbai, India. Hauptthemen laut MEDLINE: Nivolumab, Head and Neck Neoplasms. Die Arbeit wurde bisher 215-mal zitiert (Crossref) und nennt 32 Literaturangaben.
Abstract (Originalsprache)
PURPOSE The regimens approved for the treatment of advanced head and neck squamous cell carcinoma are accessible to only 1%-3% of patients in low- and middle-income countries because of their cost. In our previous study, metronomic chemotherapy improved survival in this setting. Retrospective data suggest that a low dose of nivolumab may be efficacious. Hence, we aimed to assess whether the addition of low-dose nivolumab to triple metronomic chemotherapy (TMC) improved overall survival (OS). METHODS This was a randomized phase III superiority study. Adult patients with recurrent or newly diagnosed advanced head and neck squamous cell carcinoma being treated with palliative intent with an Eastern Cooperative Oncology Group performance status of 0-1 were eligible. Patients were randomly assigned 1:1 to TMC consisting of oral methotrexate 9 mg/m 2 once a week, celecoxib 200 mg twice daily, and erlotinib 150 mg once daily, or TMC with intravenous nivolumab (TMC-I) 20 mg flat dose once every 3 weeks. The primary end point was 1-year OS. RESULTS One hundred fifty-one patients were randomly assigned, 75 in TMC and 76 in the TMC-I arm. The addition of low-dose nivolumab led to an improvement in the 1-year OS from 16.3% (95% CI, 8.0 to 27.4) to 43.4% (95% CI, 30.8 to 55.3; hazard ratio, 0.545; 95% CI, 0.362 to 0.820; P = .0036). The median OS in TMC and TMC-I arms was 6.7 months (95% CI, 5.8 to 8.1) and 10.1 months (95% CI, 7.4 to 12.6), respectively ( P = .0052). The rate of grade 3 and above adverse events was 50% and 46.1% in TMC and TMC-I arms, respectively ( P = .744). CONCLUSION To our knowledge, this is the first-ever randomized study to demonstrate that the addition of low-dose nivolumab to metronomic chemotherapy improved OS and is an alternative standard of care for those who cannot access full-dose checkpoint inhibitors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, Tata Memorial Hospital, Homi Bhabha National Institute (HBNI), Mumbai, India.
- Section of Biostatistics, Center for Cancer Epidemiology, Tata Memorial Center, Homi Bhabha National Institute (HBNI), Mumbai, India.
- Department of Speech and Therapy, Tata Memorial Hospital, Homi Bhabha National Institute (HBNI), Mumbai, India.
- Department of Radiology, Tata Memorial Hospital, Homi Bhabha National Institute (HBNI), Mumbai, India.
- Department of Nuclear Medicine, Tata Memorial Hospital, Homi Bhabha National Institute (HBNI), Mumbai, India.
- Department of Pathology, Tata Memorial Hospital, Homi Bhabha National Institute (HBNI), Mumbai, India.
ORCID-Profile: Vijay Maruti Patil, Vanita Noronha, Nandini Menon, Atanu Bhattacharjee, Mitali Alone, Archi Agarwal, Ameya Puranik, Neha Mittal, Subhash Yadav, Shripad Banavali, Kumar Prabhash
Zitieren
APA
Patil, V. M., Noronha, V., Menon, N., Rai, R., Bhattacharjee, A., Singh, A., Nawale, K., Jogdhankar, S., Tambe, R., Dhumal, S., Sawant, R., Alone, M., Karla, D., Peelay, Z., Pathak, S., Balaji, A., Kumar, S., Purandare, N., Agarwal, A., …, & Prabhash, K. (2023). Low-Dose Immunotherapy in Head and Neck Cancer: A Randomized Study. Journal of Clinical Oncology, 41(2), 222-232. https://doi.org/10.1200/jco.22.01015
Vancouver
Patil VM, Noronha V, Menon N, Rai R, Bhattacharjee A, Singh A, et al. Low-Dose Immunotherapy in Head and Neck Cancer: A Randomized Study. Journal of Clinical Oncology. 2023;41(2):222-232. doi:10.1200/jco.22.01015
BibTeX
@article{Patil2023,
author = {Patil, Vijay Maruti and Noronha, Vanita and Menon, Nandini and Rai, Rahul and Bhattacharjee, Atanu and Singh, Ajay and Nawale, Kavita and Jogdhankar, Shweta and Tambe, Rupali and Dhumal, Sachin and Sawant, Riddhi and Alone, Mitali and Karla, Devanshi and Peelay, Zoya and Pathak, Shruti and Balaji, Arun and Kumar, Suman and Purandare, Nilendu and Agarwal, Archi and Puranik, Ameya and Mahajan, Abhishek and Janu, Amit and Kumar Singh, Gunjesh and Mittal, Neha and Yadav, Subhash and Banavali, Shripad and Prabhash, Kumar},
title = {Low-Dose Immunotherapy in Head and Neck Cancer: A Randomized Study},
journal = {Journal of Clinical Oncology},
year = {2023},
volume = {41},
number = {2},
pages = {222--232},
doi = {10.1200/jco.22.01015}
}
EUVIMED